Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Dr. Reddy’s Laboratories announced the launch of Zoledronic Acid Injection, the generic version of Novartis‘ Reclast.
Reclast is a bisphosphonate indicated to treat postmenopausal osteoporosis; to reduce the incidence of new clinical fractures in patients at high risk of fractures (those with recent low–trauma hip fracture); to prevent osteoporosis in postmenopausal women; to increase bone mass in men with osteoporosis; and to treat Paget’s disease of bone in men and women. Also, it is indicated to treat and prevent glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for >12 months.
Zoledronic Acid Injection is available in a 5mg/100mL strength in single-use vials for intravenous infusion.
For more information call (908) 203-4933 or visit www.drrreddys.com.
